These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 34897475)

  • 21. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM; Bartlett DL; Cieply K; Dacic S
    Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
    Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
    Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion.
    Hustinx SR; Leoni LM; Yeo CJ; Brown PN; Goggins M; Kern SE; Hruban RH; Maitra A
    Mod Pathol; 2005 Jul; 18(7):959-63. PubMed ID: 15832197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
    Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
    Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
    Nilforoushan N; Moatamed NA
    Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
    Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
    Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
    Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
    Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence
    Cheng YY; Yuen ML; Rath EM; Johnson B; Zhuang L; Yu TK; Aleksova V; Linton A; Kao S; Clarke CJ; McCaughan BC; Takahashi K; Lee K
    Front Oncol; 2020; 10():579327. PubMed ID: 33304846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Wang JZ; Patil V; Liu J; Dogan H; Tabatabai G; Yefet LS; Behling F; Hoffman E; Bunda S; Yakubov R; Kaloti R; Brandner S; Gao A; Cohen-Gadol A; Barnholtz-Sloan J; Skardelly M; Tatagiba M; Raleigh DR; Sahm F; Boutros PC; Aldape K; ; Nassiri F; Zadeh G
    Acta Neuropathol; 2023 Jul; 146(1):145-162. PubMed ID: 37093270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    Vizcaino MA; Giannini C; Vaubel RA; Nguyen AT; Trejo-Lopez JA; Raghunathan A; Jenkins SM; Jenkins RB; Zepeda Mendoza CJ
    J Neuropathol Exp Neurol; 2024 Dec; 83(12):1003-1009. PubMed ID: 39042515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
    Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
    Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
    Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
    Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.
    Perry A; Banerjee R; Lohse CM; Kleinschmidt-DeMasters BK; Scheithauer BW
    Brain Pathol; 2002 Apr; 12(2):183-90. PubMed ID: 11958372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
    Frazão L; do Carmo Martins M; Nunes VM; Pimentel J; Faria C; Miguéns J; Sagarribay A; Matos M; Salgado D; Nunes S; Mafra M; Roque L
    BMC Cancer; 2018 Dec; 18(1):1259. PubMed ID: 30558563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.